Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Academic Teaching Hospital of the Medical Faculty of the Goethe University Frankfurt/Main, Frankfurt Main, Germany.
Br J Clin Pharmacol. 2013 Mar;75(3):630-6. doi: 10.1111/j.1365-2125.2012.04395.x.
This review deals with herbal hepatotoxicity, identical to herb induced liver injury (HILI), and critically summarizes the pitfalls associated with the evaluation of assumed HILI cases. Analysis of the relevant publications reveals that several dozens of different herbs and herbal products have been implicated to cause toxic liver disease, but major quality issues limit the validity of causality attribution. In most of these reports, discussions around quality specifications regarding herbal products, case data presentations and causality assessment methods prevail. Though the production of herbal drugs is under regulatory surveillance and quality aspects are normally not a matter of concern, low quality of the less regulated herbal supplements may be a critical issue considering product batch variability, impurities, adulterants and herb misidentifications. Regarding case data presentation, essential diagnostic information is often lacking, as is the use of valid and liver specific causality assessment methods that also consider alternative diseases. At present, causality is best assessed by using the Council for International Organizations of Medical Sciences scale ( CIOMS) in its original or updated form, which should primarily be applied prospectively by the treating physician when evaluating a patient rather than retrospectively by regulatory agencies. To cope with these problems, a common quality approach by manufacturers, physicians and regulatory agencies should strive for the best quality. We propose steps for improvements with impact on future cases of liver injury by herbs, herbal drugs and herbal supplements.
这篇综述讨论了草药性肝毒性,与草药引起的肝损伤(HILI)相同,并批判性地总结了与假定 HILI 病例评估相关的陷阱。对相关出版物的分析表明,有几十种不同的草药和草药产品被认为会导致中毒性肝病,但主要的质量问题限制了因果关系归因的有效性。在这些报告的大多数中,都围绕草药产品的质量规范、病例数据呈现和因果关系评估方法展开了讨论。虽然草药药物的生产受到监管监督,质量方面通常不是问题,但质量较低的不受监管的草药补充剂可能是一个关键问题,需要考虑产品批次变异性、杂质、掺假和草药错误识别。关于病例数据呈现,通常缺乏必要的诊断信息,也没有使用有效的和专门针对肝脏的因果关系评估方法,这些方法也考虑了其他疾病。目前,最好使用国际医学组织理事会(CIOMS)的标准来评估因果关系,以其原始或更新形式,主要由治疗医生在评估患者时前瞻性地应用,而不是由监管机构回顾性地应用。为了解决这些问题,制造商、医生和监管机构应采用共同的质量方法,争取最佳质量。我们提出了一些改进措施,以应对未来由草药、草药药物和草药补充剂引起的肝损伤病例。